Express News | GlaxoSmithKline and curevac have redefined their mRNA vaccine partnership agreement.

Breakings5minutes ago

GSK, CureVac Expand Licensing Agreement

By Anthony O. Goriainoff GSK said that under a new licensing deal with biotech company CureVac it will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or

Dow Jones15minutes ago

Express News | GlaxoSmithKline will pay 400 million euros to Curevac, a German biopharmaceutical company, and may pay up to 1.05 billion euros in the future. The two companies will carry out a reorganization cooperation.

Breakings34minutes ago

GSK Is Maintained at Buy by Jefferies

GSK Is Maintained at Buy by Jefferies

Dow Jones02:09

Jefferies Maintains Buy on GSK, Raises Price Target to $53

Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.

Benzinga01:58

GSK Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 39.51% Jefferies $52.5 → $53 Maintains Buy 05/30/2024 23.72% Goldman Sachs → $47 Initiates Cove

Benzinga01:53